Court rules in favor of Volcano/Axsun against LightLab Imaging

NewsGuard 100/100 Score

Volcano Corporation (Nasdaq: VOLC) said today that  the Superior Court of Massachusetts has issued a decision that ruled in favor of Volcano and its wholly-owned subsidiary Axsun Technologies, Inc., and against LightLab Imaging, Inc., on all of LightLab's remaining claims for trade secret misappropriation.   The 11-page decision also rejected LightLab's request for injunctive relief.  

This ruling follows prior Court rulings, in October 2010 and December 2009, that rejected other LightLab's trade secret misappropriation claims.  LightLab Imaging is a wholly-owned subsidiary of St. Jude Medical, Inc.  

"We are pleased with this ruling.  Along with prior court decisions issued in October 2010 and in December 2009, it confirms that that Volcano/Axsun are not using LightLab's purported trade secrets in our OCT development efforts.  We intend to continue developing our OCT system, and can now do so with the reassurance that the Court concurs with our position.  Volcano will continue to execute on our growth strategy of providing industry leading diagnostic and therapeutic imaging devices to improve patient outcomes," said Scott Huennekens, President and Chief Executive Officer of Volcano.

Source:

Volcano Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Understanding long COVID: A call for better diagnosis and treatment